Jeffrey Johnson is a legal writer with a focus on personal injury. He has worked on personal injury and sovereign immunity litigation in addition to experience in family, estate, and criminal law. He earned a J.D. from the University of Baltimore and has worked in legal offices and non-profits in Maryland, Texas, and North Carolina. He has also earned an MFA in screenwriting from Chapman Univer...

Full Bio →

Written by

UPDATED: Jan 15, 2020

Advertiser Disclosure

It’s all about you. We want to help you make the right legal decisions.

We strive to help you make confident insurance and legal decisions. Finding trusted and reliable insurance quotes and legal advice should be easy. This doesn’t influence our content. Our opinions are our own.

Editorial Guidelines: We are a free online resource for anyone interested in learning more about legal topics and insurance. Our goal is to be an objective, third-party resource for everything legal and insurance related. We update our site regularly, and all content is reviewed by experts.

GlaxoSmithKline’s (GSK) Type 2 diabetes drug, Avandia, has been linked to over 300 deaths in the third quarter of 2009 alone according to secret government documents obtained by the New York Times. This staggering number has prompted the U.S. Food & Drug Administration (FDA) to reassess the drug’s future in meetings this summer.

Avandia injuries / Avandia deaths

Avandia plaintiffs’ lawyers say that hundreds, if not thousands, of injuries and deaths have been linked to GSK’s Avandia (rosiglitazone) – and the latest allegations are simply unbelievable. According to confidential government information recently obtained and published by the New York Times:

[I]f every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month…

Equate those numbers to an annual basis and you’ve got staggering results. The Times reported that Dr. Kate Gelperin and Dr. David Graham, both of the FDA, concluded that Avandia should be removed from the market. Their conclusions, along with the other information recently published, has caused the FDA to take yet another look at whether Avandia should continue to be sold. It will do so this summer after convening an advisory panel.

Allegations of foul play

Many Avandia users who have been injured, and families of those who have died, after using the drug have accused GSK of foul play in order to increase the company’s bottom line. In particular, the company may have fraudulently withholding information on the safety and effectiveness of its drug. GSK settled those allegations for $2.5 million with the New York Attorney General in 2007. Even the FDA has accused GSK of withholding studies – nine different studies to be exact – after it inspected the company’s offices in North Carolina.

More damaging information about Avandia

Damaging information about Avandia is plentiful. The drug is already subject to FDA black box warnings and numerous medical journals and research facilities, such as The New England Journal of Medicine, The British Medical Journal, The American Journal of Ophthalmology, The Institute for Clinical Evaluative Science, Wake University School of Medicine and The University of East Anglia in England have said that Avandia may increase the risk of:

  • heart attack
  • heart failure
  • stroke
  • bone fracture
  • liver toxicity
  • severe vision problems such as diabetic macular edema, or DME.

Product liability lawyers say that the latest information on Avandia published by the Times may just force GSK to pull the drug off the market. However, they say that even if that happens, anyone injured by Avandia can still bring a personal injury lawsuit against the pharmaceutical giant. An experienced Avandia injury attorney can evaluate your situation in confidence and without obligation.